Story · Medicine & Biotech

AHA: Pelacarsen cuts lipoprotein(a) levels but does not lower risk for major adverse cardiovascular events

1 outlet · first reported by Medical Xpress on · latest · 24 hours of coverage

For adults with preexisting cardiovascular disease, pelacarsen, an antisense oligonucleotide administered monthly, lowers lipoprotein(a) levels but does not reduce the occurrence of major adverse cardiovascular events, according to a study published online Nov. 7 in the New England Journal of… (Medical Xpress)

Coverage, in order

  1. first Medical Xpress indie
    AHA: Pelacarsen cuts lipoprotein(a) levels but does not lower risk for major adverse cardiovascular events

    For adults with preexisting cardiovascular disease, pelacarsen, an antisense oligonucleotide administered monthly, lowers lipoprotein(a) levels but does not reduce the occurrence of major adverse cardiovascular events, according to a study published online Nov. 7 in the New England Journal of…

  2. Medical Xpress indie
    AHA: More intensive blood pressure lowering cuts future cardiovascular risk after stroke, transient ischemic attack

    For adults with previous ischemic stroke or transient ischemic attack, targeting a systolic blood pressure

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.